Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CPS1 | P31327 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334618 | 0.86 | NPC1 (0.50) | KDM4ENPC1CNR1CPS1 | |
| SCHEMBL31197153 | 0.86 | NPC1 (0.74) | NPC1CNR1KMT2AMEN1UBE2M | |
| SCHEMBL2403173 | 0.84 | KDM4E (0.51) | KDM4ENPC1CNR1KMT2AHTT | |
| SCHEMBL19461766 | 0.82 | TSHR (0.57) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL30545399 | 0.82 | TSHR (0.57) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL6411501 | 0.81 | KDM4E (0.48) | KDM4ENPC1CNR1KMT2AHTT | |
| SCHEMBL11888869 | 0.80 | KDM4E (0.54) | KDM4ENPC1CNR1KMT2AHTT | |
| SCHEMBL642396 | 0.80 | KDM4E (0.64) | KDM4ECNR1KMT2AHTTMEN1 | |
| SCHEMBL6416363 | 0.80 | KDM4E (0.46) | KDM4ENPC1CNR1KMT2AHTT | |
| SCHEMBL17868397 | 0.79 | HSD11B1 (0.53) | KDM4EKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466072-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118946566-A | Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors | 阿尔麦克探索有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | KDM4E 950/4885NPC1 1546/4885CNR1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.